2019
Native Joint Septic Arthritis: Comparison of Outcomes with Medical and Surgical Management.
Harada K, McConnell I, DeRycke EC, Holleck JL, Gupta S. Native Joint Septic Arthritis: Comparison of Outcomes with Medical and Surgical Management. Southern Medical Journal 2019, 112: 238-243. PMID: 30943544, DOI: 10.14423/smj.0000000000000958.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnkle JointAnti-Bacterial AgentsArthritis, InfectiousArthrocentesisArthroscopyCandidiasisDrainageElbow JointFemaleGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHip JointHospitalizationHumansKnee JointMaleMiddle AgedRange of Motion, ArticularRecovery of FunctionRetrospective StudiesShoulder JointStaphylococcal InfectionsSternoclavicular JointStreptococcal InfectionsTertiary Care CentersWrist JointConceptsSeptic arthritisSurgical managementCases of SADiagnosis of SARetrospective single-center studyNative joint septic arthritisSingle-center studyTertiary care hospitalLong-term outcomesLength of stayShort-term rehabilitationComparison of outcomesNative joint infectionsCare hospitalMedical managementJoint infectionRehabilitation unitInclusion criteriaEvaluated outcomesNative jointProsthetic jointsFull recoveryPatientsOutcomesSame joint
2018
Menace Elbow: Disseminated Nocardiosis
Datta R, Kramer E, Reinhart H, Campbell S, Wong E, Gupta S. Menace Elbow: Disseminated Nocardiosis. The American Journal Of Medicine 2018, 131: 1307-1309. PMID: 29729234, PMCID: PMC6482376, DOI: 10.1016/j.amjmed.2018.04.012.Peer-Reviewed Case Reports and Technical Notes
2009
Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis